Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed · Phase 3

Conditions studied: Sarcoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether doxorubicin is more effective than daunorubicin for AIDS-related Kaposi's sarcoma. PURPOSE: Randomized double-blinded phase III trial to determine if doxorubicin is more effective than daunorubicin in treating patients who have AIDS-related Kaposi's sarcoma.

Key facts

Study ID

NCT00002985

Run by

Roswell Park Cancer Institute

Starts

1996-11-01

Last updated by the study team

2013-02-04

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Roswell Park Cancer Institute — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.